Literature DB >> 29028832

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.

Marius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, Lingkang Huang, Jonathan Juco, Veronique Hofman, Paul Hofman.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0183023.].

Entities: Chemical Gene

Year: 2017 PMID： 29028832 PMCID： PMC5640228 DOI： 10.1371/journal.pone.0186537

Source DB: PubMed Journal: PLoS One ISSN： 1932-6203 Impact factor: 3.240

Fig 1 is incorrect. The authors have provided a corrected version here.

Fig 1

Optimised protocols for PD-L1 IHC assays using the 22C3 antibody concentrate on the Dako ASL48 and VENTANA BenchMark ULTRA platforms.

PD-L1, programmed death ligand 1; IHC, immunohistochemistry; ASL48, Autostainer Link 48; DAB, 3,3’-diaminobenzidine tetrahydrochloride.

Optimised protocols for PD-L1 IHC assays using the 22C3 antibody concentrate on the Dako ASL48 and VENTANA BenchMark ULTRA platforms.

PD-L1, programmed death ligand 1; IHC, immunohistochemistry; ASL48, Autostainer Link 48; DAB, 3,3’-diaminobenzidine tetrahydrochloride.

1 in total

1. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.

Authors: Marius Ilie; Shirin Khambata-Ford; Christiane Copie-Bergman; Lingkang Huang; Jonathan Juco; Veronique Hofman; Paul Hofman
Journal: PLoS One Date: 2017-08-10 Impact factor: 3.240

1 in total

Review 1. Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer.

Authors: Martín Núñez Abad; Silvia Calabuig-Fariñas; Miriam Lobo de Mena; Susana Torres-Martínez; Clara García González; José Ángel García García; Vega Iranzo González-Cruz; Carlos Camps Herrero
Journal: Cancers (Basel) Date: 2022-01-08 Impact factor: 6.639

1 in total